are our inspiration
Home / People / NOMIS Researcher / Eric M. Reiman

Eric M. Reiman

Eric M. Reiman

Eric Reiman is executive director of the Banner Alzheimer’s Institute, chief executive officer of Banner Research, senior scientist at the Translational Genomics Research Institute, professor of psychiatry at the University of Arizona, university professor of neuroscience at Arizona State University, and director of the Arizona Alzheimer’s Consortium. He led the Alzheimer’s Prevention Initiative and the Platform for the Discovery of Alzheimer’s Disease Mechanisms and Treatments projects.

Reiman received his undergraduate and medical degrees at Duke University (Durham, US) and his psychiatry residency training at both Duke and Washington University (St. Louis, US). Launching his research career as a resident and faculty member under Marcus Raichle, he and his colleagues introduced brain imaging paradigms and image analysis techniques that have had a profound impact on the study of the human mind and brain. Reiman and his Banner Alzheimer’s Institute colleagues, Pierre Tariot and Jessica Langbaum, lead the Alzheimer’s Prevention Initiative (API), which has helped to introduce a new era in Alzheimer’s prevention research. He is the author of more than 600 publications, a principal investigator of several large NIH grants and a recipient of the Potamkin Prize.

Reiman is internationally recognized for his pioneering contributions in brain imaging, genomics, and the cognitive and behavioral neurosciences; the unusually early detection and tracking of Alzheimer’s disease; and the accelerated evaluation of Alzheimer’s prevention therapies. He and his colleagues hope to find and support the approval of effective Alzheimer’s prevention therapies by 2025. They continue to find new ways for researchers from different disciplines and organizations to work together in support of their ambitious goals.

Eric M. Reiman | Awards Film

Eric M. Reiman | Insights Film

Eric M. Reiman's News

Jesús Crespo Cuaresma is professor of economics at the Vienna University of Economics and Business (WU), director of economic analysis at the Wittgenstein Centre for Demography and Global Human Capital […]

Carlos Alós-Ferrer is the NOMIS Professor for Decision and Neuroeconomic Theory at the University of Zurich (Switzerland). He co-led the project Feasibility Study: Biases and Cognitive Failures in Markets. Born […]

Jacob Corn is the Professor of Genome Biology at ETH Zurich (Zurich, Switzerland). In addition to the professorship, he is leading the Unbiased Discovery of Heterogeneous DNA Repair Preferences project. […]

When NOMIS researcher Dr. Eric Reimann was invited to join the Arizona Alzheimer Consortium in Phoenix, he was a practicing psychiatrist who did not know much about the disease. Today, […]

Christian Haass is a NOMIS board member and has been professor of biochemistry and the head of the Department of Metabolic Biochemistry at the Biomedical Research Center at Ludwig Maximilian […]

Eric M. Reiman's Insights

Abstract: The SARS-CoV2 global pandemic impacted participants in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) clinical trial, who faced three stressors: 1) fear of developing dementia; 2) concerns about missing treatment; and 3) risk of SARS-CoV2 infection. Objective: To describe the frequency of psychological disorders among the participants
Abstract: Autosomal dominant Alzheimer’s disease (ADAD) is genetically determined, but variability in age of symptom onset suggests additional factors may influence cognitive trajectories. Although apolipoprotein E (APOE) genotype and educational attainment both influence dementia onset in sporadic AD, evidence for these effects in ADAD is limited. To investigate the effects of
Abstract: We characterized the world’s second case with ascertained extreme resilience to autosomal dominant Alzheimer’s disease (ADAD). Side-by-side comparisons of this male case and the previously reported female case with ADAD homozygote for the APOE3 Christchurch (APOECh) variant allowed us to discern common features. The male remained cognitively intact until 67
Abstract: Introduction: Plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of Alzheimer's disease (AD). We investigated whether plasma p-tau217 predicts subsequent cognition and positron emission tomography (PET) markers of pathology in autosomal dominant AD. Methods: We analyzed baseline levels of plasma p-tau217 and its associations with amyloid
Abstract: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline
Björn Lillemeier

Björn Lillemeier is an associate professor in the NOMIS Center for Immunobiology and Microbial Pathogenesis and the Waitt Advanced Biophotonics Center at the Salk Institute for Biological Studies (La Jolla, […]


Introduction: Autosomal-dominant Alzheimer’s disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due […]